Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab

被引：0
|
作者：
Sang, Y. B. [1 ]
Lee, C. R. [2 ]
Kim, S-G. [1 ]
Lee, B. [3 ]
Kim, C. [1 ]
Chon, H. J. [1 ]
机构：
[1] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea
[2] CHA Bundang Med Ctr, Div Infect Dis, Dept Internal Med, Seongnam, South Korea
[3] Soonchunhyang Univ Hosp Seoul, Div Allergy & Resp Dis, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2023.10.772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
下载
收藏
页码：S1549 / S1550
页数：2
相关论文
共 50 条
  • [1] Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab
    Sang, Yun Beom
    Lee, Chaeryoung
    Kim, Seul-Gi
    Lee, Boyoung
    Kang, Beodeul
    Kim, Chan
    Chon, Hong Jae
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [2] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Esmail, Abdullah
    Xu, Jiaqiong
    Burns, Ethan A.
    Abboud, Karen
    Sheikh, Ali
    Umoru, Godsfavour
    Gee, Kelly
    Wiechmann, Catherine
    Zhang, Yuqi
    Abdelrahim, Maen
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [3] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1894 - 1905
  • [4] Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
    Yang, Xu
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xiaobo
    Zhao, Haitao
    LANCET ONCOLOGY, 2020, 21 (09): : E412 - E412
  • [5] Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
    Maesaka, Kazuki
    Sakamori, Ryotaro
    Yamada, Ryoko
    Tahata, Yuki
    Imai, Yasuharu
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Mita, Eiji
    Ito, Toshifumi
    Hagiwara, Hideki
    Yakushijin, Takayuki
    Kodama, Takahiro
    Hikita, Hayato
    Tatsumi, Tomohide
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 298 - 307
  • [6] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
    D'Alessio, Antonio
    Cammarota, Antonella
    Zanuso, Valentina
    Pressiani, Tiziana
    Personeni, Nicola
    Rimassa, Lorenza
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
  • [7] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [8] Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
    Tamaki, Nobuharu
    Tada, Toshifumi
    Kurosaki, Masayuki
    Yasui, Yutaka
    Ochi, Hironori
    Mashiba, Toshie
    Sakamoto, Azusa
    Marusawa, Hiroyuki
    Narita, Ryoichi
    Uchida, Yasushi
    Akahane, Takehiro
    Kondo, Masahiko
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kobashi, Haruhiko
    Kusakabe, Atsunori
    Furuta, Koichiro
    Arai, Hirotaka
    Nonogi, Michiko
    Ogawa, Chikara
    Sato, Takashi
    Tamada, Takashi
    Nakamura, Shinichiro
    Hasebe, Chitomi
    Tsuchiya, Kaoru
    Izumi, Namiki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1290 - 1297
  • [9] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [10] Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
    Nobuharu Tamaki
    Toshifumi Tada
    Masayuki Kurosaki
    Yutaka Yasui
    Hironori Ochi
    Toshie Mashiba
    Azusa Sakamoto
    Hiroyuki Marusawa
    Ryoichi Narita
    Yasushi Uchida
    Takehiro Akahane
    Masahiko Kondo
    Nami Mori
    Shintaro Takaki
    Keiji Tsuji
    Haruhiko Kobashi
    Atsunori Kusakabe
    Koichiro Furuta
    Hirotaka Arai
    Michiko Nonogi
    Chikara Ogawa
    Takashi Sato
    Takashi Tamada
    Shinichiro Nakamura
    Chitomi Hasebe
    Kaoru Tsuchiya
    Namiki Izumi
    Investigational New Drugs, 2022, 40 : 1290 - 1297
12345